ArticleScientific reports2017
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion.Cancer metastasis reviews · 2026Review
- 5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.International journal of molecular sciences · 2026Article
- ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Cancer chemotherapy and pharmacology · 2026Review
- Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival.The oncologist · 2026Article
- Integrated DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma.BMC cancer · 2026Article
- GCC2 in Small Extracellular Vesicles as a Diagnostic and Prognostic Biomarker of Early-Stage Lung Adenocarcinoma.Journal of extracellular vesicles · 2026Article
- Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rareFrontiers in oncology · 2026Article
- Article
- Pediatric Cutaneous Anaplastic Lymphoma Kinase-Positive Histiocytosis withDiagnostics (Basel, Switzerland) · 2025Article
- Oncogenic gene fusions in cancer: from biology to therapy.Signal transduction and targeted therapy · 2025Review
- Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboringFrontiers in immunology · 2025Review
- A Rare Case of Isolated Central Nervous System Neoplasm With Histiocytic Features.Brain tumor research and treatment · 2025Article
- Successful treatment of a non-small-cell lung cancer patient harboring HIP1-ALK (H28:A20) and CTNNB1 p.S45del with alectinib.Thoracic cancer · 2024Article
- A narrative review of methods for the identification ofTranslational lung cancer research · 2023Review
- ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.Targeted oncology · 2023Article
- ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets.Molecular therapy. Nucleic acids · 2022Article
- Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Review
- [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) represent a novel molecular target in a small subset of tumors. Although ALK rearrangements are usually assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), molecular approaches have recently emerged as relevant alternatives in routine laboratories. Here, we evaluated the use of two different amplicon-based next-generation sequencing (NGS) methods (AmpliSeq and Archer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.